Losartan
Losartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for COZAAR tablets (losartan potassium), lists three uses: treating high blood pressure in adults and children, reducing the risk of stroke in patients with high blood pressure and left ventricular hypertrophy (the label says this benefit does not apply to Black patients), and treating diabetic nephropathy in patients with type 2 diabetes and a history of high blood pressure. Cozaar is the brand name on the label read.
Also called Cozaar · Losartan potassium
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 52175; UNII 3ST302B24A. The label names the substance as losartan potassium, so UNII 3ST302B24A is the UNII of the potassium salt and is a broad match. MeSH descriptor D019808 is Losartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Organon LLC label for COZAAR (losartan potassium) tablets, application NDA020386, effective 2026-01-20 in openFDA; Drugs@FDA lists the application's sponsor as ORGANON. Other losartan labels, including generic products and fixed combinations with hydrochlorothiazide, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 21 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 21
- Phase 3 or 4
- 14
- Recruiting
- 2
- Regulatory decisions
- 0
| Phase | Recruiting | Active, not recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 5 | 0 | 2 | 7 |
| Phase 3 | 1 | 1 | 7 | 1 | 0 | 10 |
| Phase 4 | 1 | 0 | 2 | 0 | 1 | 4 |
| All phases | 2 | 1 | 14 | 1 | 3 | 21 |
Conditions these trials study
- Hypertension (high blood pressure)
- Adult congenital heart disease
- Cardiomyopathy (heart muscle disease)
- Congenital heart disease
- Dyslipidemia
- Angina pectoris
- Aortic regurgitation
- Aortic stenosis
- Cerebral small vessel disease
- Chronic kidney disease (CKD)
Sponsors with the most trials
- Hanmi Pharmaceutical Company Limited
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Arbor Pharmaceuticals, Inc.
- Chong Kun Dang Pharmaceutical
- HanAll BioPharma Co., Ltd.
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
3ST302B24A
Claims and evidence
Context Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)
- Recipient
- Child
- Population
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Label wording: children greater than 6 years old (highlights wording)
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Children with hypertension (children greater than 6 years old (highlights wording))
- Excluded
- None stated
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children greater than 6 years old (the highlights wording; a later section of the same label says pediatric patients 6 years of age and older).
Applies to Child Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children); the stroke and diabetic nephropathy indications do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults for hypertension, as the passage read states; not stated for the other indications
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Patients with hypertension and left ventricular hypertrophy (the label says the stroke benefit does not apply to Black patients)
- Patients with type 2 diabetes, a history of hypertension, nephropathy, an elevated serum creatinine and proteinuria
- Excluded
- None stated
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for application NDA020386 (COZAAR, sponsor ORGANON): product and sponsor
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA020386, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
e0ad0edb3a20d7283469925ea923a9d98524b4ca8f423e4915a9465c019d4abc- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children greater than 6 years old (the highlights wording; a later section of the same label says pediatric patients 6 years of age and older).
Applies to Child Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)
Population, setting and follow-up
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Label wording: children greater than 6 years old (highlights wording)
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ARBLI
No label from the application holder was found in the openFDA label dataset for application NDA218772. This page does not show another labeler's label in its place.
COZAAR
No label from the application holder was found in the openFDA label dataset for application NDA020386. This page does not show another labeler's label in its place.
HYZAAR
No label from the application holder was found in the openFDA label dataset for application NDA020387. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy as an indication, and says the benefit does not apply to Black patients: Stroke
Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension as an indication: Diabetic kidney disease
Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 3
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 21
Record details
- Record id
cardio:losartan- Content hash
e55023eb6ea78a13524e29bcb5f36174bb803fbd91fd4b872421f1285ee5537f